MAPT and Alzheimer disease: Ramu et al. demonstrated that treatment with fucoidan (100 and 200 mg/kg) significantly ameliorated behavioral deficits and addressed oxidative stress (reduced the MDA, AChE, and AGE contents and increased the GHS and SOD levels), the Aβ protein, and the hyperphosphorylation of the tau protein associated with streptozotocin-induced AD in rats.